1832 Asset Management
ARKG icon

1832 Asset Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

1832 Asset Management’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-654
Closed -$21.5K – 886
2023
Q4 		$21.5K Buy
+654
New +$17.8K ﹤0.01% 717
2022
Q1 		– Sell
-55
Closed -$4K – 930
2021
Q4 		$4K Buy
+55
New +$3.8K ﹤0.01% 674

Other funds holding ARKG

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

1832 Asset Management's ARKG Position: Q1 2024 in Review

1832 Asset Management sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2024, closing a stake of 654 shares — an estimated $21.5K sold.

1832 Asset Management first reported a position in ARKG in Q4 2021 and held it in 2 quarters. The position peaked at $21.5K in Q4 2023. 284 funds tracked by Wall St. Rank hold ARKG as of Q1 2024.

  • 1832 Asset Management reported no remaining ARK Genomic Revolution ETF position as of Q1 2024 after selling out during the quarter.
  • 1832 Asset Management sold 654 ARK Genomic Revolution ETF shares in Q1 2024, an estimated $21.5K.
  • 1832 Asset Management first reported a position in ARK Genomic Revolution ETF in Q4 2021 and held it in 2 quarters.
  • 1832 Asset Management's ARK Genomic Revolution ETF position peaked at $21.5K in Q4 2023.
  • 284 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2024.

Based on 1832 Asset Management's 13F filing for Q1 2024, filed 14 May 2024.